

Scientific Board

Dr Med Sergio Cortelazzo,

President of the Scientific Board

Members of the Scientific Board

Dr Med Paolo Coser

Dr Med Nicolaus Martin Kröger

Dr Med Dietger Niederwieser

Dr Med Fabio Ciceri

Dr Med Marco Casini

Dr Med Irene Cavattoni

Dr Med Sara Deola

Scientific Secretariat

Division of Hematology and BMT

General Hospital of Bolzano

Ph. +39 0471 908807

fax +39 0471 908703

e-mail: delia.orsi@asbz.it

Information

EVENT SPONSORED

Conference Venue:

the conference will be held on 2nd and 3rd November 2011 at Centro Pastorale, Conference Center in Bolzano, Piazza Duomo, nr. 2

Participants:

Medical Doctors

Official Language:

English

Suggested Parking:

Garage BZ Centro, Via Mayr-Nusser or Garage Walther, Via Stazione

Organizing Secretariat

ORGANIZING SRL

Via J. Cavacio, nr. 2 - 35128 Padova - Italy

Ph + 39 049 8025202 - Fax +39 049 8025281;

E-mail: info@organizing.it

Download CONGRESS REGULATION AND REGISTRATION FORM on

www.organizing.it



We Innovate Healthcare



Con il Patrocinio di
SIE, Società Italiana Ematologia



CME CONGRESS: 9 CREDITS

WHAT TO DO FOR REFRACTORY HEMATOLOGIC MALIGNANCIES. COMPARING ITALIAN AND GERMAN EXPERIENCES

Bolzano/Bozen, 2nd and 3rd November 2011

Sala Conferenze Centro Pastorale, P.zza Duomo, 2



Certificate number: IT-016-2011

13.40 Institutional Greetings. O. Mayr – Medical Director, General Hospital of Bolzano/Bozen.

13.45 Introduction. S. Cortelazzo

14.00 Session B-CLL . G. Pizzolo, Verona, T. Zenz, Heidelberg

14:00 Definition and impact of refractory B-CLL on clinical outcome. T. Zenz, *Heidelberg, Germany.*

14:20 Role of allotransplant in refractory B-CLL. A. Bosi, *Firenze, Italy.*

14:40 What is the best pre- and post- transplant therapy? M. Montillo, *Milano, Italy.*

15:00 Session Lymphomas. R. Fanin, Udine, N. Schmitz, Hamburg

15:00 Definition and impact of refractory lymphomas on clinical outcome. F. Zaja, *Udine, Italy.*

15:20 What is the best pre- and post- transplant therapy for NHL? P.L. Zinzani, *Bologna, Italy.*

15:40 What is the role of autologous and allogeneic transplantation in refractory lymphomas? N. Schmitz, *Hamburg, Germany.*

16:00 What is best therapy before and post-transplant for Hodgkin disease? S. Sasse, *Köln, Germany.*

16:20 MUD - or haploidentical allogeneic stem cell transplantation in Hodgkin disease. A. Dominiotto, *Genova, Italy.*

16.40 – 17.00 Coffee break

17.00 Session Multiple Myeloma. N. Kröger, Hamburg, B. Bruno, Torino.

17.00 Definition and impact of refractory Multiple Myeloma on clinical outcome. A. Larocca, *Torino, Italy.*

17.20 Allo-HSCT with non-myeloablative conditioning following autograft for the treatment of patients with Multiple Myeloma. B. Bruno, *Torino, Italy.*

17.40 What is the best pre- and post- transplant therapy? N. Kröger, *Hamburg, Germany.*

18.00 New drugs for refractory Multiple Myeloma patients. Italian experience. F. Gay, *Torino, Italy.*

18:20 Pathogenesis and management of Tumor Lysis Syndrome. S. Cortelazzo, *Bolzano, Italy.*

18.40 – 19:00 Round table and discussion

8:00 Session Acute Leukemias I. A. Rambaldi, Bergamo, D. Niederwieser, Leipzig

8:00 Definition and impact of refractory acute leukemias on clinical outcome. H. Einsele, *Würzburg, Germany.*

8:20 Early immune-phenotypic detection of refractory disease. F. Mannelli, *Firenze, Italy.*

8:40 The role of allo-HSCT in the treatment of refractory acute leukemias. The EBMT/Acute Leukemia Working Party experience. F. Ciceri, *Milano, Italy.*

9:00 Pretransplant salvage therapy and sequential conditioning in refractory disease:

9:00 Sequential conditioning Flamsa-RIC. C. Schmid, *Augsburg, Germany.*

9:20 Clofarabine, nelarabine and FLT-3 Sorafenib therapy. G. Martinelli, *Bologna, Italy.*

9.40 MRD oriented therapy in ALL. R. Bassan, *Venezia, Italy.*

10:00 Reduced or standard conditioning regimens? D. Niederwieser, *Leipzig, Germany.*

10.20 What is the best conditioning regimen for allogeneic transplantation in AML? A. Rambaldi, *Bergamo, Italy.*

10:40 Round table and discussion

11–11.20 Coffee break

11.20 Session Acute Leukemias II. M. Introna, Bergamo, U. Grigoleit, Würzburg.

11.20 Post-transplant therapy:

11.20 CIK therapy. M. Introna, *Bergamo, Italy.*

11.40 Prophylactic and therapeutic DLLI. N. Kröger, *Hamburg, Germany.*

12.00 Second allogeneic transplantation. A. Dominiotto, *Genova, Italy.*

12.20 Azacitidine as new drug. V. Santini, *Firenze, Italy.*

12.40 Haploidentical allo-HSCT in refractory acute leukemias. W. Bethge, *Tübingen, Germany.*

13.00 – 13.20 Round table and discussion

13.20 – 14.00 Lunch

14.00 – 14.20 TEST ECM

14.20 Session “old and new insights”. M. Introna, Bergamo, U. Grigoleit, Würzburg.

14.20 Allogeneic stem cell transplantation with or without ATG? P. Marengo, *Milano, Italy.*

14.40 Mechanisms of immune escape: insights from immune editing studies. L. Vago, *Milano, Italy.*

15.00 Anti Notch-1. Monoclonal Ab against T-ALL minimal residual disease. S. Indraccolo, *Milano, Italy.*

15.20 – 15.40 Round table and discussion

Treating refractory hematologic malignancies: not only “how”, but “how far?” Experience-based discussion and conclusion remarks.